Guselkumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Guselkumab: From Psoriasis to Drug-Induced Osteoporosis
One-Sentence Summary
Guselkumab is an anti-IL-23(p19) monoclonal antibody, originally developed and approved (as Tremfya) for immune-mediated inflammatory diseases such as psoriasis and ulcerative colitis. The TxGNN model’s top-ranked prediction for this candidate is Drug-Induced Osteoporosis, but this signal is currently supported by 0 clinical trials and 0 publications — it reflects knowledge-graph proximity rather than any actual evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in TFDA data for this pack (Taiwan query returned 0 results); other candidate entries in this evidence pack reference Psoriasis and Ulcerative Colitis as Tremfya’s already-approved original indications |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.84% (rank 4814) |
| Evidence Level | L5 |
| US Market Status | 未上市 (not marketed / no TFDA license found) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (data gap DG002). Based on the information that is available, guselkumab is a selective IL-23(p19) inhibitor; its efficacy in immune-mediated inflammatory conditions (psoriasis, ulcerative colitis) is documented elsewhere in this same evidence pack via other candidate indications, and mechanistically it acts by suppressing the IL-23/Th17 axis.
For the top-ranked prediction, drug-induced osteoporosis, the rationale supplied is explicitly weak: there is no direct mechanistic evidence linking IL-23 inhibition to bone loss. Osteoimmunology literature suggests an indirect relationship between the IL-23/Th17 axis and osteoclast activation, but no study has specifically connected guselkumab to drug-induced osteoporosis. The high TxGNN score most likely reflects the proximity of immune- and bone-metabolism-related nodes within the knowledge graph rather than a causal or clinical signal.
Because psoriasis (rank 3) and ulcerative colitis (rank 6) in this same evidence pack are described as guselkumab’s already-approved indications with strong supporting evidence (L1, Proceed with Guardrails), the drug-induced osteoporosis prediction should be interpreted as a low-confidence, exploratory signal — not a validated repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Guselkumab currently has no TFDA license on record in this evidence pack (market status: 未上市, total licenses: 0). No authorization data is available to tabulate.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications for this drug are marked as a Blocking data gap — DG001 — and could not be retrieved for this evaluation.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for drug-induced osteoporosis has no supporting clinical trials or literature (Evidence Level L5, Decision Stage S0) and only a speculative, indirect mechanistic rationale. The TxGNN score alone is insufficient to justify advancing this candidate.
To proceed, the following is needed:
- TFDA label warnings/contraindications (blocking gap DG001) before any safety pre-screen (S1) can begin
- Confirmed mechanism of action data (DG002) to assess mechanistic plausibility
- Preclinical or mechanistic studies specifically evaluating IL-23 inhibition and bone metabolism/osteoclast activity
- If pursuing guselkumab repurposing at all, prioritize the higher-evidence candidates already surfaced in this pack (psoriasis, ulcerative colitis) rather than this L5 signal
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.